Health and Beauty

Osteoporosis Fact Sheet

Global Generic Sterile Injectables Market Growth To Be Buoyed Beyond US$ 113 Billion By 2025 Owing To Increasing ...

According to a fact sheet released by Hospira in 2013, about 70% of the hospitals in patients receives generic sterile injectable suggesting high demands. According to WHO, the chronic diseases are the reason for Musculoskeletal is a condition that

The Media, Milk Myths and Scare-Stories

The Media, Milk Myths and Scare-Stories A number of newspapers are warning how young people cutting out dairy could be putting their bone health at risk. The National Osteoporosis Society (NOS) surveyed 2,000 adults and found that one in five 18-25 year-olds said they had cut out or reduced 

What to Do When Calcium Supplements Cause Constipation

What to Do When Calcium Supplements Cause Constipation Individuals reach peak bone mass around their early 20s, after which bone mass is lost faster than it is created.1 Thus, as an individual ages, the risk for osteoporosis increases. If age is a nonmodifiable Calcium: dietary supplement fact sheet

TGA releases codeine 'fact sheet' for consumers

TGA releases codeine 'fact sheet' for consumers The consumer fact sheet called Codeine-containing medicines: Harms and changes to patient access outlines the changes that will occur from 1 February 2018, when codeine products go prescription-only. “Most Australians are unaware that over-the-counter 

Preventive Services for Women Covered by Private Health Plans under the Affordable Care Act

Preventive Services for Women Covered by Private Health Plans under the Affordable Care Act A key provision of the Affordable Care Act (ACA) is the requirement that private insurance plans cover recommended preventive services for women without any patient cost-sharing. On December 20, 2016, the Health Resources and Services Administration 

FASLODEX® (fulvestrant) Receives US FDA Approval as ...

Jamie Freedman, Executive Vice President, Head of the Oncology Business Unit, AstraZeneca said: “We’re pleased that the landmark FALCON trial results demonstrated the efficacy of FASLODEX as initial monotherapy treatment for women who are living with HR+, HER2- advanced breast cancer. This approval, building on more than 15 years of clinical experience, means more patients can have the opportunity to receive FASLODEX earlier in the treatment journey.”

Matthew Ellis, MD, PhD, Director of the Lester and Sue Smith Breast Center, part of the NCI-designated Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine said: “This study provides evidence that using fulvestrant as the first option for previously untreated hormone receptor-positive advanced breast cancer will prolong the time before the disease advances and alternative therapies are required.”

The FALCON trial was designed to demonstrate superiority and included 462 postmenopausal women with HR+ metastatic or locally-advanced breast cancer. The results showed a statistically-significant increase in investigator-assessed median progression-free survival (PFS), representing a 20% reduction in the risk of disease progression or death determined by RECIST - median PFS of 16.6 months in patients who received FASLODEX, compared to 13.8 months in patients receiving the aromatase inhibitor ARIMIDEX

World without sunlight - scandal?

It is ridiculous how we have come to fear the sun in this modern, mad world. Should we be living like moles, underground and come out at dark? Do we panic like mad when we see a little sunlight on our shoulders? Should we start fearing moonlight?


Wrong board, this should be in health and beauty or something, anywhere but here..